AAM Statement on U.S. Court of Appeals Ruling on Maryland HB 631
WASHINGTON, DC (April 13, 2018) — Today, the United States Court of Appeals for the Fourth Circuit ruled that Maryland’s HB 631 is unconstitutional because it violates the Commerce Clause of the U.S. Constitution. As AAM has always maintained, this law, and any others modeled from it, would harm patients because the law would reduce […]
Oppose Vermont House Bill 713
Everyone supports containing skyrocketing prescription drug prices, but H.B. 713 would actually just make the problem worse for Vermont patients and our economy. The same bill is currently being litigated in Maryland and could be unconstitutional. View Brief Take Action
Poll Results: California Proposed Drug Pricing Law (SB 17)
The key findings outlined in this report were drawn from a telephone survey of 1,023 California adults conducted August 4-9, 2017. A complete description of the methodology and demographics of the sample are at the end of this summary. Overall Summary Despite few people knowing anything about SB17, a majority initially support the proposed legislation, […]
Oppose Washington Senate Bill 5995
Everyone supports finding ways to address skyrocketing prescription drug prices that seem to keep going up year after year. Unfortunately, SB 5995 doesn’t address that problem. The bill makes matters worse for Washington patients and our economy. This bill exempts the true driver of prescription drug cost increases that impact patients and taxpayer programs – […]
California SB 17 Signed Into Law
Bill fails to recognize business model of generic industry. WASHINGTON, DC (October 10, 2017) – State laws that burden manufacturers of low-cost generic and biosimilar medicines harm patients and decrease competition with expensive brand name drugs. The California bill fails to recognize that the business model of the generic industry, in which low-cost medicines can fluctuate in […]
AAM Statement on Federal District Court Ruling on HB 631
WASHINGTON, DC (September 29, 2017) – The Association for Accessible Medicines (AAM) is disappointed with the district court’s decision not to enjoin Maryland’s price gouging statute, which even the district court recognized may be unconstitutionally vague. As AAM has stated from the outset, this law will hurt patient access to safe, affordable generic medicines in […]
AAM Requests Federal Injunction to Block Maryland’s Unconstitutional Drug Price Law
Generic Pharmaceutical Trade Group Steps in to Protect Patient Access To Affordable Generic Drugs WASHINGTON, DC (JULY 6, 2017) – Today, the Association for Accessible Medicines (AAM), the trade association representing America’s manufacturers of generic and biosimilar medicines, filed a lawsuit against Maryland Attorney General Brian Frosh and Dennis Schrader, Secretary of the Maryland Department […]
Protect Generic Drug Savings for Maryland Patients and Taxpayers
Governor Hogan Should Veto Legislation To Keep Generic Drugs Affordable for Maryland WASHINGTON, DC (April 10, 2017) Generic drugs have been and continue to be an amazing success story in our healthcare system. According to the annual Generic Drug Saving and Access Report compiled by QuintilesIMS, in 2015 generic drugs delivered $227 billion in savings […]
